Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

ClinicalTrials.gov ID: NCT07005180

Public ClinicalTrials.gov record NCT07005180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

Study identification

NCT ID: NCT07005180
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hillhurst Biopharmaceuticals, Inc.; Industry
Enrollment: 36 participants

Conditions and interventions

Conditions

Parkinson Disease

Interventions

HBI-002 Drug
Vehicle (placebo) Drug

Drug

Eligibility (public fields only)

Age range: 40 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 29, 2026
Primary completion: Dec 30, 2026
Completion: Mar 30, 2027
Last update posted: Aug 9, 2026

2026 – 2027

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
The Parkinson's & Movement Disorder Institute	Fountain Valley	California	92708	Recruiting
University of Florida	Gainesville	Florida	32608	Recruiting
Quest Research Institute	Farmington Hills	Michigan	48334	Recruiting
Weill Cornell Medical College	New York	New York	10021	Recruiting
Inland Northwest Research	Spokane	Washington	99202	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07005180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 9, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07005180 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →